Litcius/Paper detail

Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience

Giulia Calabretto, Enrico Attardi, Antonella Teramo, Valentina Trimarco, Samuela Carraro, Sandra Mossuto, Gregorio Barilà, Cristina Vicenzetto, Vanessa Rebecca Gasparini, Monica Crugnola, Pasquale Niscola, Antonella Poloni, Valentina Giai, Valentina Gaidano, Carlo Finelli, Roberta Bertorelle, Cinzia Candiotto, Marco Pizzi, Gianni Binotto, Monica Facco, Fabrizio Vianello, Livio Trentin, Gianpietro Semenzato, Renato Zambello, Valeria Santini

2022Leukemia22 citationsDOIOpen Access PDF

Abstract

Myelodysplastic Syndromes (MDS) are a highly heterogeneous group of blood neoplasias characterized by myeloid dysplasia, ineffective hematopoiesis and increased risk of progression to acute myeloid leukemia We focused on hypocellular-MDS (h-MDS), a rare subtype accounting for 10-15% of MDS patients, that is defined by an age-adjusted reduction of bone marrow (BM) cellularity or, according to Aplastic Anemia definition, by a BM cellularity <30%

Topics & Concepts

Myelodysplastic syndromesMedicineInternational Prognostic Scoring SystemDysplasiaMyeloidInternal medicineMyeloid leukemiaAplastic anemiaBone marrowOncologyImmunologyAcute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationHematological disorders and diagnostics